Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, senior director of Specialty Clinical Services at Managed Health Care Associates, discusses how specialty stakeholders will need to alter current patient management programs as new drugs transform the treatment of diseases into more manageable conditions.
New guidelines for rheumatoid arthritis treatment discussed at ACR conference.
Broadly neutralizing antibody delays viral rebound and opens doors for future HIV vaccines.
ACR session reinforces the need for new research about how the genome, epigenome, and other factors play a role in rheumatoid arthritis.
CD98 molecule could be a potential therapeutic target in AML.
Comparing healthy and cancerous cells from the same individual could allow for a better understanding of translocations involved.
There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.
Vemlidy treats patients with chronic hepatitis B infection with compensated liver disease.
Top news of the day from across the health care landscape.
National Association of Specialty Pharmacy emphasizes work with manufacturers, prescribers and payers to ensure the availability of specialty medications and services that ensure optimal patient outcomes.
Specialty pharmacies must be prepared to innovate as biosimilars hit the US market.
Opdivo is approved for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma.
Gilenya may cause an increase in CD56+-expressing T cells, which can cause MS relapse.
A newly identified metabolic fingerprint of colorectal cancer may serve as a future diagnostic tool in early detection.
John Campo, vice president of Specialty Pharmacy Trade Relations and Contracting at Managed Health Care Associates, discusses optimal use of data analytics in specialty pharmacy.
Top news of the day from across the health care landscape.
Clinicians who marry technical skills with humanities can see their patients and themselves in the larger context of family, society, history, politics, and economics.
Using data and bioinformatics could hold the key to numerous treatment options.
Anti-tumor necrotic factor drugs could help delay hip deterioration in patients with ankylosing spondylitis.
Research evaluates sofosbuvir use in hepatitis C patients with a mental health disease.
Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.
Telehealth broadly is about creating care connections across boundaries, care that encourages patients’ independence, prevention and wellness; and care that can be leveraged for needed interventions. If we get telehealth right we can reduce impact of what we know is a growing health workforce shortage and concurrently create a healthier, more engaged patient base.
The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline.
Be careful what you wish for: SGR and FFS will be models of the past; the success of the APM and MIPS will rely on compensation, collaboration and participation; and, to date, much remains to be done in the development of quality-based payment reform under MACRA.
New therapeutic targets provide hope for targeted treatments for rheumatoid diseases.
JAK inhibitors may be more effective than older biologic drugs in certain patients.
New data from studies of multiple drugs highlights Janssen’s commitment to rheumatic diseases.
Pfizer will highlight successes of Xeljanz at ACR/ARHP annual meeting.
A 2-year study will examine the effectiveness of advanced MRI to determine response to breast cancer treatment.
A recent review outlines the best treatment option to prevent bone loss associated with rheumatoid arthritis.
